Stay updated on PF-06439535 vs Bevacizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the PF-06439535 vs Bevacizumab in NSCLC Clinical Trial page.

Latest updates to the PF-06439535 vs Bevacizumab in NSCLC Clinical Trial page
- Check3 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2, indicating a patch release. The Back to Top control was removed as part of this change.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%
- Check17 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous facility names and locations across various countries, particularly in South Korea, Brazil, and several European nations. Additionally, some previously listed locations and terms have been removed.SummaryDifference24%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.0%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11, indicating a revision in the content.SummaryDifference0.0%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.5%
Stay in the know with updates to PF-06439535 vs Bevacizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PF-06439535 vs Bevacizumab in NSCLC Clinical Trial page.